Insider Selling: Albireo Pharma, Inc. (NASDAQ:ALBO) Insider Sells 451 Shares of Stock

Albireo Pharma, Inc. (NASDAQ:ALBO) insider Pamela Stephenson sold 451 shares of the firm’s stock in a transaction that occurred on Monday, September 27th. The stock was sold at an average price of $32.05, for a total transaction of $14,454.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

NASDAQ ALBO traded down $0.45 during trading hours on Tuesday, hitting $31.50. 119,246 shares of the company traded hands, compared to its average volume of 195,719. Albireo Pharma, Inc. has a twelve month low of $27.23 and a twelve month high of $43.41. The stock has a market capitalization of $606.56 million, a price-to-earnings ratio of -4.29 and a beta of 1.46. The business’s 50-day moving average is $29.97 and its 200-day moving average is $32.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.23 and a current ratio of 7.23.

Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.92) by $0.02. Albireo Pharma had a negative return on equity of 82.94% and a negative net margin of 1,468.41%. The company had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.60 million. Analysts predict that Albireo Pharma, Inc. will post -6.13 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of ALBO. Royal Bank of Canada lifted its stake in Albireo Pharma by 46.1% in the first quarter. Royal Bank of Canada now owns 1,552 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 490 shares during the last quarter. E Fund Management Co. Ltd. purchased a new stake in Albireo Pharma in the first quarter worth approximately $72,000. SG Americas Securities LLC bought a new stake in Albireo Pharma in the 1st quarter worth $116,000. Metropolitan Life Insurance Co NY lifted its holdings in Albireo Pharma by 90,960.0% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 4,553 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 4,548 shares during the period. Finally, Invesco Ltd. bought a new stake in shares of Albireo Pharma during the 2nd quarter valued at $205,000. 80.85% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently issued reports on ALBO shares. Zacks Investment Research cut Albireo Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, September 21st. Robert W. Baird increased their price objective on Albireo Pharma from $67.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, July 22nd. HC Wainwright reiterated a “buy” rating and set a $79.00 price target on shares of Albireo Pharma in a research report on Wednesday, September 8th. Finally, Wedbush raised their price objective on Albireo Pharma from $82.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, September 16th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat, Albireo Pharma currently has an average rating of “Buy” and an average price target of $79.60.

Albireo Pharma Company Profile

Albireo Pharma, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat.

Featured Article: Green Investing

Insider Buying and Selling by Quarter for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.